Sensei Biotherapeutics News

Sensei Biotherapeutics Poised for Growth: A Strong Buy Rating Amid Financial Stability and Promising Clinical Trials

TipRanksMay 10 18:26

Sensei Biotherapeutics | 10-Q: Quarterly report

Futu NewsMay 10 04:48 · Announcements

Sensei Biotherapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.

Sensei Biotherapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.

BenzingaMay 9 23:19

Sensei Biotherapeutics Q1 2024 GAAP EPS $(0.32) Misses $(0.29) Estimate

Sensei Biotherapeutics Q1 2024 GAAP EPS $(0.32) Misses $(0.29) Estimate

BenzingaMay 9 20:33

Sensei Biotherapeutics 1Q Loss $7.99M >SNSE

Sensei Biotherapeutics 1Q Loss $7.99M >SNSE

Dow JonesMay 9 19:32

Sensei Biotherapeutics: Strong Balance Sheet With Cash Runway Into 4Q of 2025 >SNSE

Sensei Biotherapeutics: Strong Balance Sheet With Cash Runway Into 4Q of 2025 >SNSE

Dow JonesMay 9 19:32

Sensei Biotherapeutics: Cash, Cash Equivalents and Marketable Securities Were $58.1 M as of March 31 >SNSE

Sensei Biotherapeutics: Cash, Cash Equivalents and Marketable Securities Were $58.1 M as of March 31 >SNSE

Dow JonesMay 9 19:32

Press Release: Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limitin

Dow JonesMay 9 19:30

JAGX, SNSE and BON Among Mid-day Movers

Seeking AlphaMay 3 00:49

12 Health Care Stocks Moving In Thursday's Intraday Session

GainersEmergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out

BenzingaMay 3 00:31

Sensei Biotherapeutics to Present Topline Clinical Data From the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeut

GlobeNewswireApr 25 04:05

12 Health Care Stocks Moving In Monday's After-Market Session

GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to

BenzingaApr 23 04:31

Sensei Biotherapeutics Extends Relationship With Former CFO

TipRanksApr 13 04:43

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today

GlobeNewswireApr 9 19:30

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA Within the Tumor Microenvironment

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced the publication of a peer-reviewed research paper in Nature Communications.

GlobeNewswireApr 5 04:05

Sensei Biotherapeutics CFO Erin Colgan Resigns Amicably

TipRanksApr 2 20:02

Sensei Biotherapeutics CFO To Resign All Positions With Co Effective April 10

Sensei Biotherapeutics CFO To Resign All Positions With Co Effective April 10

BenzingaApr 2 19:48

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE) with bullish sentiments.

TipRanksMar 26 09:20

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer

GlobeNewswireMar 22 19:30

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer

GlobeNewswireMar 6 20:30